In Vivo Response Articles & Analysis
5 news found
Travera’s unique technology takes advantage of this fluid to screen the response of the live tumor cells against approved anti-cancer therapies. ...
ByxCures
MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy Data show potent anti-tumour efficacy in vivo and in vitro MB097 is in manufacturing process development for Ph1b study expected to start next year MB097 is the first microbiome precision medicine in immuno-oncology, ...
It has enabled the Company to identify the first microbiome signature predictive of response to ICI therapy across four independent melanoma studies, by analysing MELRESIST, a melanoma study conducted in collaboration with Cambridge University Hospitals. ...
Centers for Disease Control and Prevention (CDC) National Institute for Occupational Safety and Health (NIOSH) on the association of occupational exposure with ex vivo functional immune response in workers handling carbon nanotubes and carbon nanofibers (CNT/F): Matthew Dahm - CNT/F exposure assessment; Aaron Erdely - Occupational exposure and immune effects; ...
Novel technologies used at the Hamner include genomic and bioinformatics approaches for improving toxicity testing, in silico models for predictive toxicology, in vitro models that utilize human cells or cell lines to evaluate perturbations of cellular responses and in vivo models to elucidate genes that play a role in susceptibility to drug-induced toxicities. ...